Oncogenic functions and therapeutic targeting of EphA2 in cancer.

Oncogenic functions and therapeutic targeting of EphA2 in cancer.
复制标题

DOI:
10.1038/s41388-021-01714-8
复制
发表时间:
2021-04
期刊:
影响因子:
8
通讯作者:
Brantley-Sieders DM
Brantley-Sieders DM
中科院分区:
医学1区
文献类型:
--
作者:
Wilson K;Shiuan E;Brantley-Sieders DM

文献摘要

参考文献

被引文献

相似文献

超过25年的研究和临床前验证已经将EphA 2受体酪氨酸激酶定义为癌症治疗中临床转化的有前途的分子靶标。分子、遗传、生物化学和药理学靶向策略已经在体外和体内进行了广泛的测试,并且已经发现最初设计用于靶向SRC家族激酶的药物如达沙替尼也靶向EphA 2活性。其他小分子,治疗靶向抗体和肽-药物缀合物正在测试中,最近,利用针对EphA 2表达癌细胞的抗肿瘤免疫的方法已经成为一种有前途的策略。这篇综述将总结支持EphA 2在乳腺癌、肺癌、胶质母细胞瘤和黑色素瘤中的致癌作用的临床前研究,同时描述在每种情况下典型和非典型EphA 2信号传导的不同作用。该综述还总结了已完成和正在进行的临床试验,突出了靶向EphA 2治疗癌症的前景和挑战。
More than twenty-five years of research and pre-clinical validation have defined EphA2 receptor tyrosine kinase as a promising molecular target for clinical translation in cancer treatment. Molecular, genetic, biochemical, and pharmacological targeting strategies have been extensively tested in vitro and in vivo, and drugs like dasatinib, initially designed to target SRC family kinases, have been found to also target EphA2 activity. Other small molecules, therapeutic targeting antibodies, and peptide-drug conjugates are being tested, and more recently, approaches harnessing anti-tumor immunity against EphA2-expressing cancer cells have emerged as a promising strategy. This review will summarize pre-clinical studies supporting the oncogenic role of EphA2 in breast cancer, lung cancer, glioblastoma, and melanoma, while delineating the differing roles of canonical and noncanonical EphA2 signaling in each setting. This review also summarizes completed and ongoing clinical trials, highlighting the promise and challenges of targeting EphA2 in cancer.
通过激活EGFR体细胞突变的非小细胞肺癌细胞的转录分析。
DOI: 10.1371/journal.pone.0001226
发表时间: 2007-11-21
期刊: PLOS ONE
影响因子: 3.7
作者:
Choi, Kuicheon;Creighton, Chad J.;Stivers, David;Fujimoto, Nobukazu;Kurie, Jonathan M.
通讯作者: Kurie, Jonathan M.
DOI: 10.1007/s10637-012-9801-2
发表时间: 2013-02
影响因子: 3.4
作者:
Annunziata, Christina M;Kohn, Elise C;LoRusso, Patricia;Houston, Nicole D;Coleman, Robert L;Buzoianu, Manuela;Robbie, Gabriel;Lechleider, Robert
通讯作者: Lechleider, Robert
DOI: 10.1016/j.ccr.2012.11.005
发表时间: 2012-12-11
期刊: Cancer cell
影响因子: 50.3
作者:
Binda E;Visioli A;Giani F;Lamorte G;Copetti M;Pitter KL;Huse JT;Cajola L;Zanetti N;DiMeco F;De Filippis L;Mangiola A;Maira G;Anile C;De Bonis P;Reynolds BA;Pasquale EB;Vescovi AL
通讯作者: Vescovi AL
DOI: 10.1016/j.omtn.2020.02.005
发表时间: 2020-06-05
影响因子: 8.8
作者:
Affinito, Alessandra;Quintavalle, Cristina;Condorelli, Gerolama
通讯作者: Condorelli, Gerolama
DOI: 10.1038/cddis.2017.406
发表时间: 2017-08-31
影响因子: 9
作者:
Azimi A;Tuominen R;Costa Svedman F;Caramuta S;Pernemalm M;Frostvik Stolt M;Kanter L;Kharaziha P;Lehtiö J;Hertzman Johansson C;Höiom V;Hansson J;Egyhazi Brage S
通讯作者: Egyhazi Brage S